BARCODE1研究与当代前列腺癌筛查试验结果比较
本文比较了单臂BARCODE1研究(基于多基因风险评分筛查前列腺癌)与Göteborg-2和ProScreen两项当代大规模筛查试验(使用MRI联合或不联合血液标志物风险分层)的结果。BARCODE1中联合PRS与PSA或MRI使高级别前列腺癌检出较对比试验降低50-75%。作者认为PRS风险区分能力有限,不应在临床实践中采用。
要点
- BARCODE1单臂设计缺乏对照,限制其结论解释。
- 标准化后BARCODE1活检人数更多且高级别癌检出更少。
- PRS联合PSA或MRI较对比试验高级别癌检出降低50-75%。
核心结论
- 基于PRS的前列腺癌筛查表现劣于当前最佳实践,基于BARCODE1数据不应在临床采用。
研究设计与样本
- 比较BARCODE1单臂研究(基于PRS筛查)与Göteborg-2和ProScreen两项同期大规模筛查试验(使用MRI联合或不联合PC血液标志物风险分层活检)。
主要发现
- BARCODE1诊断低级别前列腺癌126例,Göteborg-2为103例,ProScreen为41例。
- BARCODE1检出高级别前列腺癌155例,Göteborg-2为178例,ProScreen为165例。
- BARCODE1中联合PRS与PSA或MRI使高级别前列腺癌检出较Göteborg-2和ProScreen降低50-75%。
临床怎么用
- 基于BARCODE1数据,PRS筛查不应在临床实践中采用。
局限性
- BARCODE1缺乏对照臂,限制其发现的可解释性;PRS风险区分能力有限,无法优先检出侵袭性疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Polygenic risk scores (PRSs) have generated considerable interest as a means of personalizing prostate cancer (PC) screening by stratifying individuals according to their genetic risk. The single-arm BARCODE1 study recently showed that PRS-based screening detected more PCs than prostate-specific antigen (PSA) testing or magnetic resonance imaging (MRI). The absence of a comparator arm limits the interpretability of this finding. We compared outcomes from BARCODE1 with those from two contemporaneous, large-scale screening trials-Göteborg-2 and ProScreen-that used MRI with or without a PC blood marker to risk-stratify men for biopsy. When standardized to 10 000 men tested, BARCODE1 biopsied more men (704 vs 386 and 338), diagnosed more low-grade PCs (126 vs 103 and 41), and detected fewer high-grade PCs (155 vs 178 and 165) versus Göteborg-2 and ProScreen. Combining PRS with PSA or MRI in BARCODE1 reduced the detection of high-grade PCs by 50-75% in comparison to Göteborg-2 and ProScreen. These findings reflect the limited risk discrimination of PRSs and their inability, unlike MRI and blood-based markers, to preferentially detect aggressive disease. PRS-based PC screening underperforms relative to current best practice and, on the basis of BARCODE1 data, should not be adopted in clinical practice.
引用
- Sud A, McNeill A, Vickers AJ, et al. Comparison of Results from the BARCODE1 Study and Contemporary Prostate Cancer Screening Trials. Eur Urol Oncol. 2025. PMID: 41478782. doi:10.1016/j.euo.2025.12.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。